Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly
Recruiting in Palo Alto (17 mi)
Age: 65+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Restorbio Inc.
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.
Research Team
SS
Sarb Shergill, PhD
Principal Investigator
Restorbio Inc.
Eligibility Criteria
Inclusion Criteria
Male and female subjects
Age ≥ 85 years
Asthma
See 6 more
Treatment Details
Interventions
- BEZ235 (Dual PI3K/mTOR Inhibitor)
- BEZ235 plus everolimus (RAD001) (Dual PI3K/mTOR Inhibitor and mTOR Inhibitor)
- Placebo (Other)
Participant Groups
4Treatment groups
Experimental Treatment
Placebo Group
Group I: BEZ235 twice daily for 16 weeksExperimental Treatment1 Intervention
Group II: BEZ235 plus RAD001 once daily for 16 weeksExperimental Treatment1 Intervention
Group III: BEZ235 once daily for 16 weeksExperimental Treatment1 Intervention
Group IV: Placebo once daily for 16 weeksPlacebo Group1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Restorbio Inc.
Lead Sponsor
Trials
5
Recruited
1,800+